Ariano R, Panzani R C, Chiapella M, Augeri G, Falagiani P
Allergology Department, Ventimiglia Hospital, Italy.
J Investig Allergol Clin Immunol. 1995 May-Jun;5(3):126-32.
Local Intranasal Immunotherapy (LII) is a new approach to the treatment of allergic rhinitis due to the pollen of Parietaria officinalis. The aim of this study was to verify the usefulness of LII and to determine the proper doses. Twenty adult patients all presenting a sensitization to the pollen of Parietaria officinalis were randomly divided into two groups: 15 received the treatment and five were the control group. Treatment started before the beginning of the pollinic season of Parietaria officinalis and continued during the season. The extract used was an active extract of macronized powder Parietaria officinalis pollen in increasing doses. Doses were determined periodically with specific nasal provocation tests. Results in the treated group compared to the control group were statistically significant if one considers the increase in threshold sensitivity in the nasal provocation test, the diminution of clinical symptomatology and the quantity of drug required to control symptoms in the treated group. The side effects were few; it was only in one case that the treatment had to be interrupted. LII for allergic rhinitis due to the pollen of Parietaria officinalis seems an effective and practicable method even during the pollinic season.
局部鼻内免疫疗法（LII）是一种治疗由药用墙草花粉引起的过敏性鼻炎的新方法。本研究的目的是验证LII的有效性并确定合适的剂量。20名均对药用墙草花粉过敏的成年患者被随机分为两组：15人接受治疗，5人作为对照组。治疗在药用墙草花粉季节开始前开始，并在该季节期间持续进行。所使用的提取物是大颗粒化粉末药用墙草花粉的活性提取物，剂量逐渐增加。剂量通过特定的鼻激发试验定期确定。如果考虑到鼻激发试验中阈值敏感性的增加、临床症状的减轻以及治疗组中控制症状所需的药物量，治疗组与对照组相比的结果具有统计学意义。副作用很少；仅在1例中治疗不得不中断。对于由药用墙草花粉引起的过敏性鼻炎，即使在花粉季节，局部鼻内免疫疗法似乎也是一种有效且可行的方法。
